 |
Prospector
Profile
1221-11
|
| |
| Champions Biotechnology, Inc. |
NAICS |
541710 |
| 2200 Wilson Boulevard, Suite 102-316
Arlington, VA 22201 |
Description |
Biotechnology |
| (703) 526-0400 |
Employees |
1 |
| http://www.championsbiotechnology.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.1700 |
| |
Assets |
(mil) |
0.1830 |
| |
Liability |
(mil) |
0.4440 |
| |
(for the year ended 2007-04-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Champions Biotechnology, Inc. reported a net loss of $145,563 for the second quarter ended Oct. 31, 2007, compared with a net loss of $19,568 for the same period ended Oct. 31, 2006. The company had $0 operating revenues in both comparable periods. At Oct. 31, 2007, the company's consolidated balance sheet showed $1.2 million in total assets, $394,343 in total liabilities, and $825,227 in total stockholders' equity. The company's consolidated balance sheet at Oct. 31, 2007, also showed strained liquidity with $365,919 in total current assets available to pay $394,343 in total current liabilities.
|
| |
|
Intellectual Property:
In February 2007, the Company acquired the patent rights to two Benzoylphenylurea (BPU) sulfur analog compounds that have shown promising potent activity against in vitro and in vivo models of prostate and pancreatic cancer. The acquired rights include pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs. [SEC Filing 10-KSB 08-14-07]
|
| |
|
Description:
The Company focuses on the evaluation, acquisition, and early stage development of a portfolio of new therapeutic drug candidates.
|
| |
|
Officers:
James M. Martell (Chair, Pres., CEO & CFO); Dr. David Sidransky (Dir.); Dr. Manuel Hidalgo (Scientific Advisor & Dir.); Durwood C. Settles (Treas. & Dir.); Michael M. Tomic (Dir.)
|
| |
|
Auditor:
Bagell Josephs Levine & Company LLC
|
| |
|
Securities:
Common Stock-Symbol CBSR.OB; OTC BB;
31,624,658 common shares outstanding as of August 10, 2007.
|
| |
| |
| |
| return to main page |
|
|
